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Abstract
Combination chemotherapy is a common practice in clinical management of malignancy. 
Synergistic therapeutic outcome is only achieved when tumor cells are exposed to cells in an 
optimal ratio. However, due to diverse physicochemical properties of drugs, no free drug cocktails 
or nanomaterials are capable of co-loading and co-delivering drugs at an optimal ratio. Herein, we 
develop a novel nano-platform with precise ratiometric co-loading and co-delivery of two 
hydrophilic drugs for synergistic anti-tumor effects. Based on previous work, we utilize a solvent 
displacement method to ratiometrically load dioleoyl phosphatidic acid (DOPA)-gemcitabine 
monophosphate and DOPA coated cisplatin-precipitate nanocores into the same PLGA NP. These 
cores are designed to have similar hydrophobic surface properties. GMP and cisplatin are 
engineered into PLGA NP at an optimal synergistic ratio (5:1, mol:mol) with over 70% 
encapsulation efficiency and were ratiometrically taken up by tumor cells in vitro and in vivo. 
These PLGA NP exhibit synergistic anti-cancer effects in a stroma-rich bladder tumor model. A 
single injection of dual drugs in PLGA NP can significantly inhibit tumor growth. This 
nanomaterial-system solves problems related to ratiometric co-loading and co-delivery of different 
hydrophilic moieties and provides possibilities for co-loading hydrophilic drugs with hydrophobic 
drugs for combination therapy.
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Combination therapy is particularly effective in the treatment of HIV/AIDs and cancer. It 
provides a general means to maximize therapeutic efficacy, overcome treatment resistance, 
and diminish adverse effects.[1] Optimized doses and molar ratios of combined drugs are 
critical to promote synergistic rather than antagonistic effects.[2] However, differential 
pharmacokinetics and distribution of individual drugs within the conventionally 
administered “cocktail” lead to deviation from the optimized ratio during systemic delivery. 
This fact makes predicting improved in vivo therapeutic outcomes from in vitro synergistic 
effects a real clinical challenge.[3] Nanomaterial-based delivery is one approach to unifying 
dual-drug pharmacokinetics.[2c] However, it is rather difficult to load drugs with drastically 
different physical chemistry into the designed nano-carriers, which is why only a few 
nanoparticulate formulations [4] were able to reach the goal. Although attempts have been 
made, precise loading and ratiometric delivery of drugs with diverse solubility, steric 
configuration and other physicochemical properties still remains a challenge.[5] Moreover, 
combining individual therapeutic blocks together without interference their own 
functionalities adds to the complexity of compact nanostructures for combination drug 
delivery.[6]
Cisplatin is considered the gold standard in several first-line combination therapies.[7] A 
nanoparticulate approach used to enhance the ratio-dependent synergistic cisplatin-related 
combination therapy is rarely reported due to the difficulties in loading cisplatin along with 
other types of drugs into a single NP and the possible chemical interference with other 
groups of drugs such as nucleic acids.[8] Limited solubility of inorganic cisplatin in both 
water and oil significantly hinders the development of NP with high drug loading and 
encapsulation efficacy.[9] Gemcitabine monophosphate (GMP), an organic hydrophilic drug, 
was chosen for combination therapy with cisplatin. It is well known that Gemcitabine is 
widely used as a first line therapy in combination with cisplatin for the treatment of bladder 
cancer. However, Gemcitabine relies on nucleoside transporters [10] to enter into cells where 
it is subsequently phosphorylated by deoxycytidine kinase to form active intermediates for 
DNA synthesis interference. GMP is one of the active intermediates of Gemcitabine.[11] 
Since the addition of the first phosphate group in GMP formation is the rate-limiting step, 
we anticipate GMP to be an efficient therapeutic drug candidate with great commercial 
value that can exhibit a synergistic effect in combination with cisplatin.[12] Due to the 
significant difference in physicochemical properties, co-encapsulation of cisplatin and GMP 
is difficult. Therefore, NP that can ratiometrically co-encapsulate and co-deliver native 
cisplatin and GMP while not compromising the drug activity, are highly desired.
Previously in our lab, we developed dioleoyl phosphatidic acid (DOPA) coated calcium 
phosphate cores with the capability of loading hydrophilic phosphorylated drugs (such as 
GMP core)[13], small interfering RNA (siRNA)[14], DNA[15] and peptides[16]; as well as 
DOPA coated cisplatin cores (CP core), where cisplatin serves as both nanocarrier and anti-
cancer drug.[9, 17] The surface and size similarities between these two categories of cores 
provide us a methodology to unify a wide range of drugs or biomolecules with drastically 
disparate solubility and polarity into a standardized hydrophobic physicochemical property. 
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Unifying physicochemical characteristics of dual drugs is the prerequisite for ratio-
controlled loading and delivery.
Based on this rationale, we report a novel strategy to achieve both precise ratiometric 
loading and delivery of cisplatin with GMP. Cisplatin and GMP were originally formulated 
into DOPA coated CP cores and DOPA coated GMP cores. As shown in Figure 1A, PLGA 
NP are used to incorporate these two separate hydrophobic cores. Since CP cores and GMP 
cores have similar surface properties, we therefore hypothesize that these two drugs can be 
ratiometrically encapsulated into the same PLGA NP. To demonstrate our hypothesis, CP 
cores and GMP cores were co-loaded into single PLGA NP using the solvent displacement 
method (Figure 1A). Ratiometric loading of GMP and cisplatin were first examined. With 
the confirmation of ratiometric loading property of PLGA NP, we further proposed that this 
dual-drug containing NP could be ratiometrically delivered to the site of malignancy at the 
optimal ratio (Figure 1B). This hypothesis was tested in vitro via release kinetics study and 
cellular uptake study, and in vivo via tumor accumulation analysis. We then hypothesized 
that co-delivery of both drugs at an optimized ratio would result in synergistic anticancer 
efficacy. A stroma-rich human bladder cancer xenograft model was used to evaluate the 
anti-tumor efficacy of dual-drug containing NP at optimized ratio.[18] Synergistic anti-
cancer effect was further determined via protein based mechanistic analysis. To our 
knowledge, this is the first time that cisplatin has been reported to be co-encapsulated with 
another hydrophilic drug in the same NP with precise ratiometric control.
2. Results and Discussions
2.1. Preparation and Characterization of Single Drug Loaded PLGA NP
GMP cores and CP cores were prepared as previously mentioned [9, 13] and characterized as 
8-12 nm in diameter as determined by transmission electron microscopy (TEM) (Figure 
S1). Encapsulation efficiency (EE) of GMP in the GMP core was 60.6 ± 4.3% (n=5) as 
measured by absorbance of GMP at 273 nm. CP cores were also prepared with an EE of 
40.4 ± 1.4% (n=5) as measured by inductively coupled plasma mass spectrometry (ICP-
MS). Both GMP cores and CP cores could be well dispersed into organic solvent, such as 
tetrahydrofuran (THF). The above results indicated that hydrophilic GMP and cisplatin have 
been successfully loaded into hydrophobic cores respectively and these cores were ready to 
be further incorporated into PLGA NP.
High and comparable encapsulation efficiency of each component is a prerequisite for 
controlled loading of several modalities in the same nanoparticle. Therefore, single drug 
loaded PLGA NP were initially investigated and characterized. PLGA NP were originally 
conjugated with polyethylene glycol (PEG) to prolong systemic circulation time and then 
self-assembled with PLGA and DOPA coated cores into PLGA NP via single step solvent 
displacement (Figure 1). Briefly, polymer and drug containing cores were dissolved in THF, 
a water-miscible solvent, and poured drop wise into water. NP was formed instantaneously 
during this rapid solvent diffusion process. Anisamide, an agonist of the sigma receptor, was 
also introduced into PLGA NP as a ligand to enhance internalization in epithelium-derived 
cancer cells, which overexpress the sigma-receptor (Figure S2).[19] Results in Figure S3 
indicate that both GMP and cisplatin in DOPA coated core structures can be encapsulated 
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into PLGA NP separately with high EE (70.6 ± 2.5% and 74.0 ± 10.1%, respectively, n=5) 
at drug loading (DL) of up to approximately 5 wt%. This is the first time that GMP and 
cisplatin have been engineered into PLGA NP using solvent displacement method. This 
method proved much more efficient than loading free gemcitabine and cisplatin into PLGA 
NP via the double emulsion method, whose maximum loading is only around 1 wt%.[20] 
Notably, free cisplatin and GMP are quite polar and cannot be loaded into PLGA NP using 
the solvent displacement method; and thus, DOPA coated cores not only provide an 
approach to load different types of drugs, especially hydrophilic drugs, into PLGA NP using 
solvent displacement, but also facilitate hydrophilic drugs to be loaded into PLGA NP with 
higher DL and EE. More importantly, the EE for single free drugs in PLGA NP using this 
novel preparation method is quite comparable to each other, suggesting the possibility of 
loading different drug moieties simultaneously into the same NP at similar EE but different 
dual-drug ratios,which is one indispensable parameter for ratiometric loading.
2.2. Precise Ratiometric Control over Dual-Drug Loading in Combo NP
The success of loading GMP cores and CP cores into PLGA NP provides us with the 
possibility to encapsulate two different drug-containing cores into a single NP in a 
ratiometric manner. To confirm that CP cores and GMP cores can be ratiometrically co-
loaded into PLGA NP (Combo NP), several further studies were investigated. Firstly, total 
feed loading of GMP and cisplatin in Combo NP was fixed at 6 wt% while the feed molar 
ratio between GMP and cisplatin was altered from 0.5:1 to 5:1 (Figure 2A). Results 
indicated that the measured molar ratio between the two drugs in Combo NP was almost the 
same as the feed molar ratio (0.52 vs 0.5; 0.97 vs 1; 3.3 vs 3, 5.3 vs 5) and the EE of both 
drugs, which all remained above 70% with subtle fluctuation, was almost identical as well. 
Next, the feed molar ratio of GMP to cisplatin was set at 5 (Figure 2B). It was found that the 
measured molar ratio of GMP to cisplatin in Combo NP was approximately 5 when the total 
loading of the two drugs was below 6 wt%. Additionally, greater than 80% EE was 
achieved. In both experiments, particle size measured by dynamic light scattering (DLS) 
was under 120 nm and polydispersity of the dual drug particles was around 0.2 (Figure S4). 
Thus, these results demonstrated that ratiometric loading of distinct types of drugs in DOPA 
coated cores could be achieved over a wide dual drug ratio range and loading efficiency.
2.3. Characterization of Dual-Drug Loaded Combo NP using TEM and XPS
To demonstrate that GMP cores and CP cores are homogenously distributed in each Combo 
NP, we further characterized the Combo NP with total drug feeding ratio of 6 wt% and feed 
GMP/cisplatin ratio of 5, whose determined loading was 5.5 ± 0.8 wt% (n=5) and molar 
ratio between GMP and cisplatin was 5.3. TEM revealed Combo NP as spherical and mono-
dispersed with a diameter of approximately 90-120 nm (Figure 2C), which is consistent with 
the value measured by DLS (average 120 nm) (Figure S5). In addition, large quantities of 
well-dispersed cores were clearly clustered in each NP, further confirming the hypothesis of 
a nanocapsule-like structure with high and efficient drug loading (Figure 2C). Notably, each 
NP contained a similar amount of cores. However, TEM result alone cannot show the 
homogeneous distribution of cores in NP. Therefore, we further characterized the Combo 
NP using high resolution TEM with energy dispersive spectroscopy (EDS) analysis and x-
ray photoelectron spectroscopy (XPS). Chemical element analysis using EDS indicated that 
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both fluorine (characteristic element of GMP) and platinum (characteristic element of 
cisplatin) were present in single NP (Figure 2D). Over 20 particles were analyzed to 
determine the average molar ratio of GMP and cisplatin inside each NP. The ratio of 
fluorine to platinum, representing the ratio of GMP to cisplatin, was approximately 4.9 ± 
1.9, which is comparable to the feed ratio of 5 and the determined ratio in bulk solution of 
5.3. This result demonstrated that the two distinct cores were present in single NP and their 
ratio was precisely controlled. To avoid disturbance of neighboring oxygen on fluorine 
quantification, XPS was carried out to further confirm the ratiometric distribution of the two 
drugs. Combo NP was dissolved in THF, and a 5 nm layer of particle lysates were analyzed 
by XPS. The spectrum in Figure 2E indicates that fluorine could be separated well from 
oxygen, and the calculated molar ratio of GMP to cisplatin was approximately 5.6, similar to 
the results determined using other techniques. Therefore, quantifications from the single 
particle nano-layer of particle lysate as well as the bulk solution strongly suggest the fact 
that the dual-drug combination has been successfully, homogenously loaded into single 
Combo NP with relatively precise ratiometric control.
2.4. In Vitro Ratiometric Control over Dual-drug Cellular Uptake
In vitro synergy studies of free cisplatin and GMP (Combo free) using Chou-Talalay 
method[21] indicated that Combo free exhibited the strongest synergy at a GMP/cisplatin 
ratio of 5 in human urinary bladder carcinoma UMUC3 cell line.[18] We incorporated 3H-
labeled CMP (cytidine monophosphate) into single GMP cores in PLGA NP (GMP NP) as a 
marker to detect the concentration of GMP. In vitro cellular uptake (Figure S6) of free GMP 
and free cisplatin indicated that UMUC3 cells exhibited an equivalent uptake of GMP and 
cisplatin, suggesting that the feed ratio and the actual intracellular ratio of the drug 
combination was almost identical in the in vitro assay (Figure 3A). However, the uptake of 
drugs in the tumor cells in vivo will be much different due to differing PK profiles and the 
complicated tumor microenvironment. In order to maintain the ratio of drugs in vivo and 
utilize the strongest synergy of Combo free at a GMP/cisplatin ratio of 5, PLGA NP with a 
total drug loading of 5.5 ± 0.8 wt% (n=5) and molar ratio between GMP and cisplatin of 5.3 
were further investigated in the following studies. Single drug PLGA NP with a feed ratio of 
6 wt% was used for comparison (Table S1). Notably, the size of CP cores in single PLGA 
NP (cisplatin NP) was smaller (approximately 60 nm) than that of GMP NP and Combo NP. 
This is not surprising considering that CP cores are denser than GMP cores which are 
mainly composed of calcium phosphate.
Ratiometric cellular uptake of both GMP and cisplatin by UMUC3 cells is a prerequisite to 
evaluating synergistic effects. Cellular uptake of GMP and cisplatin in separate NP was 
compared with that of the dual-drug combination in Combo NP (Figure 3A). Results 
indicated that Combo NP ratiometrically transported drugs into cells, which is consistent 
with the results from Combo free, while a mixture of separate NP (Sepa NP) cannot 
maintain the predetermined ratio of drugs because smaller cisplatin NP deliver their cargo 
into cells more efficiently than the larger GMP NP. This ratiometric uptake of Combo NP 
was also observed over a longer incubation of NP with cells (Figure 3B).
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2.5. In Vitro Ratiometric Control over Dual-drug Release from PLGA NP
After verifying that Combo NP can ratiometrically transport the drugs into cells, we then 
studied the extracellular and intracellular release of Combo NP. The in vitro release kinetics 
of cisplatin and GMP from Combo NP, cisplatin NP and GMP NP were first investigated via 
dialysis in PBS (pH=7.4) at 37 °C for 96 h. The amount of platinum released from NP was 
measured by ICP-MS, while 3H-labeled CMP served as a marker for the measurement of 
GMP. It is notable that only negligible burst release was observed when the drugs inside 
DOPA-coated cores were encapsulated in PLGA NP (Figure 3C), although burst release 
phenomenon is well known and commonly observed for hydrophilic drugs in PLGA 
nanoparticulate formulation.[20, 22] For example, cisplatin incorporated PLGA15K-PEG5000 
NP have shown a burst release in the initial 4 h with a release fraction of approximately 50% 
and gemcitabine encapsulated PLGA NP have shown 60% liberated drug in the initial 6 
h[20a, 23]. This suggests that the DOPA layer prevents burst release of GMP and cisplatin 
from PLGA NP. Release kinetics of these two drugs in combination was further analyzed by 
grouped t-tests, which showed that there was no significant difference between these two 
drugs (p=0.78). This observation suggests that dual drugs in Combo NP followed a 
ratiometric release profile. The subtle difference in release rate may be due to the different 
composition of CP cores and GMP cores, yet the difference can be neglected when 
compared to the release rate of drugs from PLGA NP, which is a key rate-limiting step of 
the procedure. This indicates that release of cisplatin and GMP can be controlled at a similar 
rate and in a ratiometric manner when co-encapsulated into single PLGA NP. In order to 
further mimic the acidic endosome microenvironment[24], a release kinetics study was also 
carried out in pH 5.6 PBS for 96h. There were subtle changes in the release kinetics of the 
drugs and the ratio-controlled release of the dual drugs in Combo NP was still well-
maintained (Figure S7).
Intracellular release of drugs from Combo NP was then studied. UMUC3 Cells were first 
incubated with Combo NP for 1, 4, or 16 h and subsequently washed. At each time points, 
cells were lysed with RIPA buffer, followed by separation of NP and free drugs via 
centrifugation at 16,000 g for 20 min. We found this method can extract more than 98% of 
NP and free drugs from cells with little destruction of NP. Results in Figure 3D indicated 
that a controlled and ratiometric release of cisplatin and GMP were also observed in the 
UMUC3 at the cellular level.
2.6. In Vitro Synergistic Effect of Combo NP
The in vitro cytotoxicity of free drugs and drug-loaded PLGA NP were evaluated by using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results 
showed that although subtle differences between the half-maximal inhibitory concentration 
(IC50) of free cisplatin and cisplatin NP existed, GMP NP resulted in a much lower IC50 of 
17.8 μM compared with GMP free drug (IC50 of 34.8 μM), indicating that targeted NP 
delivery can maintain or enhance the cytotoxicity in vitro (Figure 3E). In addition, data 
revealed blank PLGA NP containing CaP core with negligible toxicity (data not shown). To 
validate the in vitro synergistic effect of Combo NP with dual-drug molar ratio of 5.3:1 
(GMP:cisplatin), the combination index (CI) was further determined using the isobologram 
equation of Chou–Talalay.[21] As shown in Figure 3F, Combo NP displayed an overall CI 
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value < 1 when Fa value was in the validated range of 0.2 to 0.8, indicating the pronounced 
and clear synergy of PLGA combo therapy in vitro.
2.7. In Vivo Anti-cancer Efficacy of Combo NP on Stroma-riched Bladder Xenograft Tumor 
Model
As previously mentioned, one of the most fundamental principles behind this formulation is 
to controllably deliver dual drugs into the tumor with an optimized ratio so as to achieve an 
enhanced anti-tumor efficacy in vivo. Therefore, different treatments were evaluated in an 
aggressive stroma-rich bladder cancer model, which was established by subcutaneously co-
inoculating UMUC3 cells along with fibroblast NIH 3T3 cells in matrigel. Tumors were 
allowed to develop until their volume reached 100~150 mm3. Tumor bearing mice were 
then treated with a total of 3 injections at a dose of 12 mg/kg GMP and 1.9 mg/kg cisplatin 
in Combo NP. Cisplatin and GMP prepared in separate PLGA NP (Sepa NP) were 
administrated simultaneously in a mixture for comparison. Previous study in our lab has 
shown that blank PLGA NP have no tumor inhibition effect.[25] As shown in Figure 4A, 
free drugs showed little inhibitory effect at the same dose and dose schedule, possibly due to 
low tumor accumulation; while single drugs in PLGA NP demonstrated an enhanced 
therapeutic efficacy compared with free drugs. This is due to the EPR effect and receptor 
mediated endocytosis mentioned earlier. Dual drugs in Combo NP inhibited the growth of 
UMUC3 tumors most significantly without reducing the body weight (Figure 4A and Figure 
S8), indicating the enhanced anti-cancer effect and the safety of cisplatin and GMP in 
combination compared to single drugs. However, when the dual drugs were dosed together 
in a mixture (i.e., Sepa NP), tumor inhibition seemed to be compromised and the tumor 
weight on the last day of measurement was significantly higher than that of the Combo NP 
(Figure 4A). To further confirm the potent anti-cancer efficacy of Combo NP in the 
aggressive UMUC3 tumor model, a single injection of high dose Combo NP was 
administered and compared with low dose at regular dosing intervals. Results indicated that 
GMP and cisplatin in single high dose Combo NP showed potent efficacy, which is 
comparable to the effect of low dose at regular dosing intervals. Thus, only single injection 
could inhibit tumor growth in the aggressive stroma-rich tumor model (Figure 4C).
2.8. In Vivo Ratiometric Control over Dual-drug Tumor Accumulation in Xenograft Tumor 
Model
We postulated that Combo NP were more efficient in inhibiting growth of the tumor than 
Sepa NP due to the fact that Combo NP may deliver cisplatin and GMP into the tumor at the 
predetermined optimized synergistic ratio and dose. Tumor accumulation data indicated 
ratiometric accumulation of GMP and cisplatin from Combo NP over 10 h post injection 
(Figure 4B). However, higher uptake of cisplatin NP and lower uptake of GMP NP was 
observed after dosing with Sepa NP. On one hand, smaller particle size (around 60 nm) can 
account for higher tumor accumulation of cisplatin in single PLGA NP, while on the other 
hand, compared with 5.5 wt% loading of dual drugs in single PLGA NP, the same dose of 
4.4 wt% cisplatin and 4.2 wt% GMP in separate PLGA NP doubles the amount of injected 
anisamide modified PLGA NP, which can result in saturation of sigma receptors and 
subsequently reduce the accumulation of GMP in tumors. This observation suggests 
advantages in controlling the ratio of drugs in DOPA coated cores in single PLGA NP over 
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a mixture of separate NPs, which have variant physicochemical properties and distinct 
pharmacokinetics. Variations in the loaded ratio and actual amount of drug taken up by 
tumor tissues can directly affect the anti-tumor efficacy induced by synergy. In addition, 
nanoparticles also increased the tumor accumulation of free drugs from 2% ID/g to more 
than 10% ID/g due to the EPR effect and enhanced internalization into tumor cells through a 
receptor mediated pathway.
2.9. Combo NP Triggered Significant Tumor Cell Apoptosis and Inhibited Tumor Cell 
Proliferation Effectively In Vivo in Stroma-rich UMUC3 Xenografts
Enhanced antitumor efficacy of Combo NP was confirmed via analysis of apoptosis and 
proliferation. Tumor tissues after treatment were further sectioned for TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) assay and PCNA (proliferating cell 
nuclear antigen) immunohistochemistry (Figure 5A and Figure 5B). Results indicated that 
Combo NP induced apoptosis in 28.8% of cells in UMUC3 xenograft tumors. Dual drugs in 
Sepa NP caused more cell apoptosis compared with cisplatin NP and GMP NP treatment, 
but were still significantly less efficient in inducing apoptosis than Combo NP. Free drugs 
induced few apoptotic cells in vivo, probably because the majority of the free drugs were 
metabolized and cleared before they accumulated in the tumor. In addition, the inhibition of 
tumor cell proliferation was investigated using PCNA assay. PCNA is expressed in the cell 
nuclei during DNA synthesis and can be used as a marker for cell proliferation. PCNA 
results were consistent with those of TUNEL assay. Combo NP showed minimal amounts of 
PCNA positive cells. These data further illustrated that combined drugs in a single NP 
inhibited the growth of the tumor through enhanced induction of apoptosis and reduced cell 
proliferation.
2.10. Mechanism of Synergistic Effect of the Dual-Drug Combo NP
In order to validate the observed enhanced antitumor effect of Combo NP is a synergistic 
effect imposed by GMP and cisplatin in the NP, subsequent studies were designed 
accordingly from a mechanistic basis. It is reported that gemcitabine potentiates the 
accumulation of cisplatin damage by suppressing the expression of key proteins involved in 
nucleotide excision repair (NER) and mismatch repair (MMR), leading to a decreased repair 
of Pt-DNA adducts, and thereby suppressed repair of cisplatin-induced DNA lesions.[12b, 26] 
Therefore, intensified inhibition of DNA repair and Pt-DNA adduct removal are two signs 
of synergistic interaction. The effect of combination therapy on ERCC1 and XPA[12b], two 
major proteins with key roles in NER was first examined by western blotting and showed 
that down-regulation of ERCC1 and XPA was induced by GMP free drug and enhanced by 
GMP NP treatment (Figure 5C). Combo NP almost completely depleted the expression of 
ERCC1 and XPA and was more efficient than Sepa NP. To study the effect of down-
regulation of ERCC1 and XPA on Pt-DNA repair, Pt-DNA adducts were stained with FITC-
labeled anti Pt-DNA adduct antibody. As shown in Figure 5D, a significant increase in the 
amount of Pt-DNA adducts was observed when tumors were treated with Combo NP, 
compared with that of Sepa NP.
The level of cleaved PARP and Caspase-3 were observed in order to further investigate the 
relationship of the suppressed DNA repair proteins and apoptosis. During the execution 
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phase of apoptosis, intact PARP is mainly cleaved by caspase-3 or caspase-7 to a larger 
fragment and a smaller fragment. Therefore, PARP cleavage serves as a reliable marker of 
apoptosis.[13, 27] Figure S9 indicated that cleaved PARP was significantly elevated after 
treatment with Combo NP, which is consistent with the results of the DNA repair proteins 
and Pt-DNA adduct formation. Caspase-3 was also elevated after Combo NP treatment. 
Conclusively, Combo NP exhibited greater efficacy in inhibiting DNA repair and 
suppressing the removal of Pt-DNA adducts, leading to intensified apoptosis compared to 
dual drugs in separate NP in vivo. These results further verify that Combo NP acted in a 
synergistic fashion rather than only additive fashion to induce the enhanced anti-cancer 
effect in the stroma-rich bladder cancer xenograft model.
2. 11. Evaluation of Systemic Toxicity of Combo NP
Another important issue involved with combination therapy is the dual-drug distribution and 
ratio in major organs, as well as, the association of synergistic effects with toxicity in these 
organs. Quantitative biodistribution analyses of GMP and cisplatin in Combo NP indicated 
that the ratio of dual drugs remained constant in almost all organs (Figure S10). Similar to 
other nano-platforms, the major particle uptake organs were the liver (approximately 20% 
ID/g tissue) and the spleen (approximately 40% ID/g tissue) 10 h post injection. However, 
free drugs were eliminated rapidly from the body leaving the kidney as the major 
accumulation organ, which also explains the common nephrotoxicity of free cisplatin. Due 
to different particle size, cisplatin and GMP in separate nanoparticles presented very 
different distribution behaviors in vivo. Notably, cisplatin NP showed significantly higher 
accumulation in spleen, which might be a potential factor for inducing spleen toxicity.
Since the major side effect of GMP is myelosuppression and cisplatin can also induce an 
accumulated decrease in hematopoietic cell counts, a blood routine test was performed on 
healthy nude mice with three dosages of the 8 treatment groups. Both free GMP and 
cisplatin significantly reduced the levels of red blood cells (RBC), platelets (PLT) and white 
blood cells (WBC) compared to untreated control (Figure S12). Combination of these free 
drugs slightly potentiates the toxicity. Although there was an inevitable amount of 
accumulation of NP in the liver and kidney, blood biochemistry tests showed that NP 
coating can slightly alleviate the chemo-drug induced myelosuppression. There is no 
noticeable aggravation of blood toxicity in Combo NP. WBC, RBC, hematocrit (HCT), 
hemoglobin (HGB) of Combo NP were all close to the value of the untreated control 
(Figure S12).
Other hematological parameters showed that no detectable damage was caused; aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) and blood urea nitrogen (BUN) 
analyses were all within the normal range (Table S2). No noticeable histological changes 
were seen in H&E-stained tissue sections of the liver, kidney and spleen (Figure S11). 
These studies demonstrated that Combo NP, with the most significant synergistic 
therapeutic efficacy, have elevated tumor uptake and low spleen accumulation, and as well 
exhibited no significant toxicity to major organs and tissues. Therefore, ratiometric 
synergistic combination therapy with non-overlapping toxicity is a promising strategy in 
overcoming drug resistance while enhancing anti-cancer effect.
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Developing NP to simultaneously encapsulate drugs with different physicochemical 
properties with precise ratiometric loading and delivery is extremely important in the 
combination chemotherapy of malignant diseases. In the present study, we have successfully 
developed single nanocapsule-like PLGA particles with payloads of GMP cores and 
cisplatin cores. These dual-drug loaded NP exhibited precise ratiometric control over drug 
loading, cellular uptake, in vitro release and in vivo tumor accumulation. Furthermore, this 
single NP with well-controlled optimal dual-drug ratio exhibited a more significant 
antitumor efficacy compared with dual drugs in a mixture of separate NPs. Overall, our 
studies provide a solution to the problems of formulating cisplatin and other groups of 
hydrophilic drugs for ratiometric combination therapy and have therefore distinguished this 
single nanoparticulate delivery platform as an efficient and relatively safe candidate in the 
treatment of human bladder cancer.
This nanomaterial-system with spatially separated modalities prevents functional 
interference between individual molecules. Also, this system provides a possible well 
controlled platform for co-delivery chemotherapy with other hydrophobic ligand coated 
inorganic NP (e.g. ion oxide NP, gold NP, quantum dots and upconversion NP) for 
photothermal and theranostic purposes.
4. Experimental Section
Chemicals and Materials
Gemcitabine monophosphate disodium salt (GMP, purity ≥97%) was generously provided 
by Qualiber, Inc. (Chapel Hill, NC). Cisplatin was purchased from Sigma-Aldrich (Dorset, 
UK). Dioleoyl phosphatidic acid (DOPA) was obtained from Avanti Polar Lipids, Inc. 
(Alabaster, AL). mPEG3000-NH2.HCl and tBOC-PEG3500-NH2.TFA were purchased from 
JenKem Technology USA Inc. (Allen, TX). Acid terminated PLGA was ordered from 
DURECT Corporation (Cupertino, CA). N,N-diisopropylethylamine (DIPEA), 1-ethyl-3-(3-
(dimethylamino)-propyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), 
dichloromethane, triton™ X-100, Igepal® CO-520, p-Anisic acid, silver nitrate and 
cyclohexane were purchased from Sigma-Aldrich (St Louis, MO) without further 
purification.
Cell Culture
The mouse embryonic fibroblast cell line (NIH 3T3) was obtained from UNC Tissue Culture 
Facility. The human bladder transitional cell line (UMUC3) was generously provided by Dr. 
William Kim (University of North Carolina at Chapel Hill, NC). These two cell lines were 
cultured in Dulbecco’s Modified Eagle’s Media (DMEM) (Invitrogen, Carlsbad, CA), 
supplemented with streptomycin (100 Ug/mL) (Invitrogen), penicillin (100 U/mL), and 10% 
Bovine calf serum (Hyclone, Logan, Utah) or 10% fetal bovine serum (Sigma, St. Louis, 
MO) respectively. Cells were cultured in a humidified incubator at 37 °C with 5% CO2.
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Female athymic nude mice used in all the studies weighed between 28-22 g and were 6-8 
weeks of age. They were provided by the University of North Carolina animal facility. 
Animals were cared for in the Center for Experimental Animals (an AAALAC accredited 
experimental animal facility) at the University of North Carolina. Experimental animal 
handling procedures were performed following the protocols conformed to the Guide for the 
Care and Use of Laboratory Animals and approved by the University of North Carolina 
Institutional Animal Care and Use Committee.
Synthesis of PLGA-PEG-MBA and PLGA-mPEG
Briefly, for the synthesis of PLGA-PEG-MBA, tBoc-PEG3000-NH2.HCl (1 eq), anisic acid 
(8 eq) and DIPEA (4 eq) were dissolved in DCM and added with DIC (8 eq) to react for 26 
h to obtain MBA-PEG-Boc. After purification and structure confirmation by NMR, Boc 
protecting group was removed using a TFA/DCM (1:2, v/v) mixture to achieve MBA-PEG-
NH2.TFA. Afterwards, MBA-PEG-NH2.TFA was conjugated to PLGA (15 kDa, 0.1 mmol) 
in the presence of DIPEA and DIC for 26 h and purified. PLGA-PEG-MBA structure was 
confirmed by NMR. In the synthesis of PLGA-mPEG, mPEG-NH2.TFA (3000, 0.126 
mmol), PLGA (15 kDa, 0.1 mmol) and DIPEA (0.5 mmol) were dissolved in 6 ml DCM and 
reacted with DIC (1.0 mmol) for 24 h.
Preparation of CP cores
CP cores were prepared as previously mentioned with a little adjustment.[9, 17] First, 300 μL 
of 200 mM cis-[Pt(NH3)2(H2O)2](NO3)2 was dispersed in a mixed solution of cyclohexane/
triton-X100/hexanol (75:15:10, V:V:V) and cyclohexane/Igepal CO-520 (71:29, V:V) to 
form a well-dispersed reversed micro-emulsion. Another reversed micro-emulsion 
containing KCl was prepared by adding 300 μL of 800 mM KCl aqueous solution to a 
separate oil phase. Then, 500 μL of DOPA (20 mM) was added to the cisplatin precursor 
phase and the mixture was stirred. Twenty minutes later, the two emulsions were mixed and 
reacted for another 20 min. Forty mL of ethanol was then added to break the micro-emulsion 
and the mixture was centrifuged at 10,000 g for at least 15 min. The pellets were washed 
with ethanol 2 more times to ensure the complete removal of the surfactants and 
cyclohexane, and then re-dispersed in 2.0 mL of chloroform for storage.
Preparation of GMP cores
GMP cores were synthesized according to our previous work with a little adjustment.[27] 
Briefly, 100 μL of 60 mM GMP was mixed with 500 μL of 25 mM Na2HPO4 and then 
dispersed in 20 mL of oil phase containing Igepal CO-520/cyclohexane (29:71, V:V). The 
other emulsion was prepared by adding 600 μL of 2.5 M CaCl2 into a separate oil phase. 
Six-hundred mL of 20 mM DOPA was added to the phosphate phase before mixing of the 
two separate emulsions. Another 400 μL of 20mM DOPA was added to the combined 
emulsion 5 min after mixture. The emulsion was stirred for another 20 min and then 40 mL 
of ethanol was added. Next, the mixture was centrifuged at 10,000 g for 15 min to remove 
the surfactants and cyclohexane. After being washed with ethanol 2–3 times, the pellets 
were re-dispersed in 2.0 ml of chloroform for storage.
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Preparation of PLGA/PLGA-PEG/PLGA-PEG-MBA (4:4:2) NP (PLGA NP) Loaded with cores
Drug encapsulated cores were loaded into PLGA NP using a single step solvent dispersion 
method as previously described with little adjustment.[25] Briefly, 2 mg of polymers and the 
cores were dissolved in 200 Ul of THF and added dropwise into 2 ml of water with 
continuous stirring at room temperature. Then, the NP suspension was stirred uncovered for 
6 h at room temperature in order to remove the residual THF. The resulting NP were further 
purified by ultrafiltration (3000 × g, 15 min, Amicon Ultra, Ultracel membrane with 50,000 
NMWL, Millipore, Billerica, MA). The obtained PLGA NP were then re-suspended, washed 
twice with water, centrifuged at 14,000 rpm for 20 min to further remove free lipids and 
micelles. And then re-suspended again and centrifuged at 800 rpm to remove nanocore 
aggregations.
Characterization of PLGA NP
DL and EE of cisplatin were measured using Inductively Coupled Plasma-Mass 
Spectroscopy (ICP-MS, NexIONTM 300, Perkin Elmer Inc); LE and EE of GMP were both 
measured by Ultraviolet–Visible Spectroscopy (UV, DU®800, Beckman Coulter) and 3H 
labeled cytidine 5’ monophosphate (CMP) [5-3H] disodium salt (Moravek Bio Inc, 1 
mCi/mL) incorporation using a Liquid Scintillation Analyzer (TRI-CARB 2900 TR, Packard 
Bioscience Co). The size distribution of particles was determined using a Malvern ZetaSizer 
Nano series (Westborough, MA). TEM images of NP were obtained using a JEOL 100CX II 
TEM (JEOL, Japan). For NP imaging, the NP were negatively stained with 2% uranyl 
acetate. The composition of PLGA combo NP was studied using Electron Dispersive 
Spectroscopy (EDS) (Oxford instruments, INCA PentaFET -x3) and X-ray photoelectron 
spectroscopy (XPS) (Kratos Axis Ultra DLD X-ray Photoelectron Spectrometer).
Cellular Uptake Study in UMUC3 Cell Lines
UMUC3 cells were seeded into a 12-well plate (1.5 × 105 cells/well) containing 1 ml of 
media. Twenty-four hours later, 1 ml of the free drug combination, targeted PLGA Combo 
NP, targeted PLGA Sepa NP, 20%-targeted PLGA Combo NP or non targeted PLGA 
Combo at a concentration of 20 μM GMP and 3.8 μM cisplatin were incubated with cells in 
a serum-free medium. Four hours later, cells were treated with RIPA buffer (Sigma-
Aldrich). The concentration of cisplatin was measured using ICP-MS and GMP was 
measured as 3H-CMP using a scintillation counter as previously mentioned.
In Vitro Release and Intracellular Release of cisplatin and GMP from PLGA NP
The dialysis technique was employed to study the in vitro release of GMP and cisplatin from 
PLGA in phosphate buffered saline (PBS) (pH 7.4 or pH 5.6) at 37 °C. Five hundred μL of 
PLGA NP loaded with 100 μg/mL of GMP and cisplatin separately or co-loaded with 100 
μg/mL of GMP and cisplatin at a ratio of 5.33:1 were added into the dialysis tube with a 
molecular weight cut off of 3000 Da and dialyzed against 15 mL of PBS (pH 7.4 or pH 5.6) 
in a thermo-controlled shaker with a stirring speed of 200 rpm at 37 °C for 96 h. In the 
preparation of GMP cores, a trace amount of radioactive 3H-CMP was mixed with GMP to 
serve as a marker for the entrapped GMP. At each predetermined time point, 400 μL 
samples were taken and replaced with fresh media. Platinum and GMP concentrations were 
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then determined by ICP-MS and scintillation analyzer respectively at specified times. All 
experiments were performed in triplicate and the data were reported as mean ± SD of the 
three individual experiments. Measuring of intracellular release of free drugs from the 
nanoparticles was carried out according to a previous protocol.[9] Briefly, a 12-well plate of 
UMUC3 cells was prepared as mentioned in the uptake study and incubated with 20 μM of 
GMP and 3.8 μM of cisplatin encapsulated into PLGA Combo NP. After 1, 4, and 16 hours, 
the cells were treated with 50 μL of RIPA buffer (Sigma-Aldrich) at 4°C for 10 min and the 
cell lysate was centrifuged at 14,000 rpm for 20 min at 4°C to separate nanoparticle and cell 
lysate from free drugs. Free drugs and nanoparticles were measured using ICP-MS and 3H-
labeled scintillation. All experiments were performed in four replicates and the data reported 
as mean ± SD.
In vitro Cell Viability on UMUC3 Cells and Analysis of Synergistic Effects of Drug 
Combinations
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was conducted 
to detect in vitro viability of free GMP, cisplatin and their combinations as well as PLGA 
GMP NP, PLGA cisplatin NP and PLGA Combo NP. In Brief, cells were seeded in 96-well 
plates with a density of 3,000 cells per well 24 h prior to drug treatment. On the second day, 
cells were treated with free drugs or the drug combination at a series of dilutions with 
various molar ratios. Forty-eight h post treatment, 20 μL of MTT (5 mg/mL) reagent was 
added for another 4 h at 37 °C. The medium was then discarded and the formed formazan 
salt was dissolved in 150 μL of DMSO. The absorbance in each well was read at the 
wavelength of 570 nm using a multidetection microplate reader (Plate CHAMELEON™ V-
Hidex).Each concentration was tested in five wells and data presented as mean ± SD. The 
mean drug concentration required for 50% growth inhibition (IC50) was calculated using 
CompuSyn software (Version 1.0, Combo-Syn Inc., U.S.) with the median effect equation: 
Fa=[1+(IC50/D)m]−1, where, m is the Hill slope, D is drug concentration and Fa is the 
fraction of affected cells.
Combination Index (CI) Analysis of free drug combination based on the Chou and Talalay 
method[21] was conducted using CompuSyn software. Briefly, for each level of Fa, the CI 
values of cisplatin and GMP combinations were calculated according to the following 
equation: CI=(D)1/(Dx)1+(D)2/(Dx)2, where (Dx)1 and (Dx)2 are the concentrations of the 
drugs alone resulting in Fa×100% growth inhibition, while (D)1 and (D)2 are the 
concentrations of each drug in the combination leading to Fa×100% growth inhibition. CI 
values of the drug combinations were drawn as a function of Fa. CI values more than 1 or 
less than 1 indicate antagonism or synergism of drug combinations, respectively. Notably, 
CI values between Fa 0.2 to 0.8 are considered validate.[28]
Tumor Accumulation of GMP and Cisplatin in Stroma-rich Xenograft Bladder Tumor Model
A stroma-rich subcutaneous xenograft bladder tumor model was established previously in 
our lab.[18] Briefly, UMUC3 (5×106) and NIH 3T3 cells (2×106) in 100 μL of PBS were 
subcutaneously co-injected into the right flank of mice along with Matrigel (BD 
Biosciences, CA) at a ratio of 3:1 (v/v). When the tumor reached 100-150 mm2 in size, 
animals were randomly divided into three groups (n=8) and intravenously injected with free 
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GMP and cisplatin (Combo Free), PLGA Combo NP and PLGA Sepa NP at a dose of 12 
mg/kg GMP and 1.9 mg/kg cisplatin respectively. Trace fraction of 3H-CMP was added to 
the GMP related groups for the measurement of tumor accumulation of GMP. Four mice 
from each group were sacrificed at each predestined time point and tumor tissues were 
collected. Tumor uptake of GMP and cisplatin was expressed as the percentage of the 
injected dose per gram tumor. For measurement of GMP, 10-20 mg of tumor tissue was 
immediately mixed with 10× NCS® II Tissue Solubilizer (Amersham Biosciences, Inc) and 
digested at 60°C overnight. Three hundred μL of hydrogen peroxide (30% in water, Fisher) 
was then added to the samples and vortexed to bleach the color. The sample was then mixed 
with 4 mL of scintillation cocktail (Fisher Inc). The radioactivity of 3H in the tumor samples 
was counted using a liquid scintillation analyzer (TRI-CARB 2900 TR, Packard Bioscience 
Co.). For the measurement of cisplatin, 25-35 mg of tumor tissue was digested with 400 μL 
60% nitric acid (Acros Organic) at 70°C overnight and the amount of platinum was 
measured by ICP-MS.
Biodistribution of Dual Drug in Major Organs
Mice were administered a single dose of Combo Free, PLGA Sepa NP and PLGA Combo 
NP respectively at a dose of 1.9 mg/kg cisplatin and 12 mg/kg GMP. Each group contained 
four mice, which were sacrificed 10 h following injection. Tissue samples were digested as 
previously mentioned in the tumor accumulation study. Cisplatin was quantified via ICP-MS 
and GMP via scintillation counter.
Anti-tumor Efficacy in Stroma-rich Xenografts
When the inoculated tumor reached 100-150 mm2 in size, mice were randomized into eight 
groups (n=5) as follows: Untreated Control (PBS), free GMP (GMP free), free cisplatin 
(Cisplatin Free), combination of free GMP and cisplatin (Combo free), PLGA GMP NP, 
PLGA cisplatin NP, GMP and cisplatin PLGA NP mixtures (PLGA Sepa NP) as well as 
PLGA Combo NP. IV injections were performed every three days for a total of three 
injections with a GMP dose of 12 mg/kg and a cisplatin dose of 1.9 mg/kg. Tumor volume 
was measured every day. Body weight was also recorded. Mice were sacrificed two days 
after the last injection and tumor tissues were collected for further study.
TUNEL Assay
All the immunofluorescence detections mentioned in this manuscript on UMUC tumor 
bearing mice were prepared using paraffin embedded sections (prepared by the UNC Tissue 
Procurement Core). Slides were deparaffinized through xylene and a graded alcohol series 
and prefixed with 4% formaldehyde. Apoptosis was then detected by TdT-dependent dUTP-
biotin nick end labeling (TUNEL) assay using an apoptosis detection kit (Promega, 
Madison, WI) following the manufacturer’s instructions. Slides were then coverslipped 
using VECTASHIELD with DAPI (Vector laboratories, Burlingame, CA). All staining was 
evaluated and digital images were acquired by an Eclipse Ti-U inverted microscope (Nikon 
Corp., Tokyo, Japan) at 20× magnification. Five randomly selected microscopic fields were 
quantitatively analyzed using Image J (National Institutes of Health).
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Proliferation of tumor cells after the aforementioned treatments was detected by antibody 
against proliferating cell nuclear antigen (PCNA) (1:200 dilution, Santa Cruz).[13] The 
paraffin embedded tissue sections were deparaffinized, antigen recovered, blocked and 
probed with PCNA antibody overnight at 4°C, and then detected using a mouse-specific 
HRP/DAB detection IHC kit as recommended by the manufacturer (Abcam, Cambridge, 
MA). Cell nuclei were counter-stained with hematoxylin. The percentage of proliferative 
cells was calculated by dividing the number of PCNA positive cells (shown as brown dots) 
by the number of total cells (blue nuclei stained by hematoxylin). Five representative 
microscopic fields were randomly selected in each treatment group for quantification.
Platinum Adduct staining
The platinum-DNA adducts were detected using anti-cisplatin modified DNA antibodies 
[CP9/19] (Abcam, Cambridge, MA).[9] The tumor sections were deparaffinized, antigen 
recovered, blocked with 1% BSA/PBS for 1h at room temperature, incubated with a 1:250 
dilution of anti-cisplatin modified DNA antibody [CP9/19] at 4°C overnight, and then 
incubated with FITC-labeled goat anti-rat IgG antibody (1:200,Santa Cruz, CA). The 
sections were also counter-stained with VECTASHIELD mounting media with DAPI 
(Vector laboratories, Burlingame, CA). The tumor sections were observed and quantified 
using a Nikon light microscope (Nikon Corp., Tokyo, Japan).
Western-blot Analysis
Two days after three daily IV injections, UMUC tumor bearing mice were sacrificed and 
tumor tissues were collected and lysed using radioimmunoprecipitation assay (RIPA) buffer 
(Sigma-Aldrich). The concentration of total protein in the tumor lysate was quantified using 
bicinchoninic acid (BCA) protein assay reagent following the manufacturer’s instruction 
(Invitrogen). After dilution with 4× sample buffer containing reducing agent and heating at 
95 °C for 5 min, forty μg of protein per lane was separated by 4-12% SDS-PAGE 
electrophoresis (Invitrogen). The proteins were then transferred to polyvinylidene difluoride 
(PVDF) membranes (Bio-Rad). The membranes were blocked with 5% skim milk for 1 h 
and incubated overnight at 4°C with mouse monoclonal poly(ADP-ribose) polymerase-1 
(PARP-1) antibodies, mouse monoclonal ERCC1, mouse monoclonal XPA (12F5). GAPDH 
antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) was used as the internal loading 
control. The membranes were washed three times and then incubated with a secondary 
antibody (1:4000 dilution; Santa Cruz biotechnology, Inc.) at room temperature for 1 h. 
Goat anti-mouse secondary antibody was used for PARP, XPA and ERCC-1 primary 
antibody. Goat anti-rabbit secondary antibody was used for GAPDH primary antibody. 
Finally, the membranes were washed four times and detected using the Pierce ECL Western 
Blotting Substrate according to the manufacturer’s instructions (Thermo Fisher Scientific).
Serum biochemical value analysis and hematology assay
After three injections, blood was collected and centrifuged at 4000 rpm for 5 min to obtain 
the serum. Blood urea nitrogen (BUN), creatinine, serum aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) levels, were assayed as indicators of renal and hepatic 
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function. Whole blood was collected from healthy nude mice after three repeated treatments. 
Red blood cells (RBC), white blood cells (WBC), platelets (PLT), hemoglobin (HGB) and 
hematocrits (HCT) were counted for the detection of myelosuppression. Organs (heart, liver, 
spleen, lung, and kidney) were fixed and sectioned for H&E staining as to evaluate the 
organ-specific toxicity.
Statistical Analysis
Quantitative results were expressed as mean ± SD. The analysis of variance was completed 
using student's t-test and one-way analysis of variance (ANOVA). A p value of p < 0.05 was 
considered statistically significant.
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Refer to Web version on PubMed Central for supplementary material.
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Fabrication of PLGA-PEG-Anisamide NP (PLGA NP) containing CP cores and GMP cores 
via a single step solvent displacement method (A). Cisplatin and GMP, which are 
ratiometrically encapsulated in PLGA NP, are ratiometrically delivered into the tumor and 
exhibit strong synergistic anti-tumor efficacy (B).
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Dual-drug ratiometric loading in Combo NP. EE and DL of GMP and cisplatin in Combo 
NP while the total loading of drugs was fixed at 6 wt% (A); EE and DL of GMP and 
cisplatin in Combo NP while the feed molar ratio of GMP to cisplatin was fixed at 5:1 (B); 
TEM image of 5.5 wt% total drug loading of Combo NP with molar ratio of GMP and 
cisplatin of 5.3:1 (C). EDS spectra of Combo NP (D). Both platinum from CP cores and 
fluorine from GMP cores were observed in a single NP indicating actual loading of dual 
drugs in single NP. XPS spectrum of Combo NP (E). Molar ratio of GMP and cisplatin was 
also quantified using atomic ratio of fluorine and platinum. Spectrum of Pt 4F and spectrum 
of F 1S, from which, area of peaks are integrated for atom quantification.
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Ratiometric cellular uptake and release of dual drugs from Combo NP. Uptake of cisplatin 
and GMP in Combo NP, Sepa NP, and free drugs at 37 °C for 4 h in UMUC3 cells (A). 
Accumulative uptake of Combo NP loaded with cisplatin and GMP in UMUC3 Cells (B). In 
vitro release kinetics of cisplatin and GMP from Combo NP and single NP in PBS at 37 °C 
(C) and intracellular release of cisplatin and GMP from Combo NP (D). IC50 of free GMP, 
cisplatin, and Combo free at molar ratio 5.3:1, as well as single drug NP and Combo NP at 
molar ratio 5.3:1 (E). X-axis indicated the total concentration of dual drugs or single drug 
formulations. The corresponding CI vs Fa plots of Combo NP and Combo free were shown 
(F). DL of cisplatin and GMP in Combo NP is 0.8 wt% and 4.6 wt% respectively, while DL 
of cisplatin and GMP in single NP is 4.4 wt% and 4.2 wt% respectively. n.s.: no significant 
difference; * P<0.05; ** P<0.01.
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Tumor inhibition effects of free drugs, Combo free, cisplatin NP, GMP NP, Sepa NP and 
Combo NP on a stroma-rich UMUC3 bladder cancer xenograft model (A). Red arrows in 
panel A indicate time of injection. The tumors were treated with three IV injections at a dose 
of 1.9 mg/kg cisplatin and 12 mg/kg GMP in all the treatment groups. Tumor accumulation 
of cisplatin and GMP was calculated 10 h post injection of Combo NP, Sepa NP and Combo 
free at the injection dose of 1.9 mg/kg cisplatin and 12 mg/kg GMP into nude mice bearing 
stroma-rich bladder cancer xenograft tumors (B). Anti-tumor effects of multiple low dosing 
schedule and single high dosing schedule were compared (C). N=5; * P<0.05; ** 
P<0.01; #P >0.2; ## P>0.5; n.s: non-significant difference. ID/g: injected dose per gram 
tissue (tumor)
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Apoptosis (A) and proliferation (B) of tumor cells in vivo after administration of different 
treatments. Expression of XPA and ERCC-1, common in nucleotide excision repair (NER) 
systems, after three dosage systemic treatments (C). The formation of Pt-DNA adduct 
(green) in tumor cells detected by anti-Pt-DNA adduct antibody after systemic treatment 
(D). Bar chart in D is a quantitative analysis of % of Pt-DNA adduct in tissue sections. Five 
randomly selected microscopic fields were quantitatively analyzed on Image J. * P<0.05; ** 
P<0.01.
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Table 1





GMP & CDDP PLGA
Combo NP
DL (wt%) 4.4 ± 0.6 4.2 ± 0.3 5.5 ± 0.8
EE (%) 74.0 ± 10.0 69.5 ± 1.6 86.6 ± 1.9 & 92.4 ± 1.6
(n=3)
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Table 2
Effect of Different Treatments on serum ALT, AST, BUN and creatinine levels
Treatment BUN mg/dL Creatinine mg/dL AST U/L ALT U/L
PBS 19 ± 1 0.2 228 ± 13 60 ± 14
Cisplatin free 25 ± 1 0.2 216 ± 15 59 ± 1
GMP free 24 ± 2 0.2 122 ± 20 47 ± 3
Combo free 22 ± 5 0.2 116 ± 18 60 ± 4
Cisplatin NP 28 ± 3 0.2 245 ± 22 58 ± 11
GMP NP 21 ± 1 0.2 86 ± 6 42 ± 2
Sepa NP 29 ± 2 0.3 238 ± 10 55 ± 8
Combo NP 18 ± 3 0.2 122 ± 12 52 ± 12
Normal Range 12 - 33 0.2 - 0.9 54 - 298 17 - 132
(n=5)
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